JP2024535041A5 - - Google Patents
Info
- Publication number
- JP2024535041A5 JP2024535041A5 JP2024516809A JP2024516809A JP2024535041A5 JP 2024535041 A5 JP2024535041 A5 JP 2024535041A5 JP 2024516809 A JP2024516809 A JP 2024516809A JP 2024516809 A JP2024516809 A JP 2024516809A JP 2024535041 A5 JP2024535041 A5 JP 2024535041A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- concentration
- composition according
- immunoglobulin
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111112052 | 2021-09-18 | ||
| CN202111112052.4 | 2021-09-18 | ||
| PCT/CN2022/119187 WO2023040999A1 (zh) | 2021-09-18 | 2022-09-16 | 包含pd-l1抗原结合片段的组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535041A JP2024535041A (ja) | 2024-09-26 |
| JP2024535041A5 true JP2024535041A5 (https=) | 2025-09-17 |
Family
ID=85602449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516809A Pending JP2024535041A (ja) | 2021-09-18 | 2022-09-16 | Ｐｄ－ｌ１抗原結合断片を含む組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240382411A1 (https=) |
| EP (1) | EP4403575A4 (https=) |
| JP (1) | JP2024535041A (https=) |
| CN (1) | CN118215681A (https=) |
| AU (1) | AU2022348783A1 (https=) |
| CO (1) | CO2024009127A2 (https=) |
| WO (1) | WO2023040999A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CA3007135A1 (en) * | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CN109966487B (zh) * | 2017-12-28 | 2023-08-25 | 上海复宏汉霖生物制药有限公司 | 一种包含抗pd-l1单克隆抗体的药物配制剂 |
| KR20210096640A (ko) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | 항-pd-l1 항체 제제 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 |
| IL295511A (en) * | 2020-02-18 | 2022-10-01 | Amgen Inc | Formulations of human anti-tslp antibodies and methods of using them |
-
2022
- 2022-09-16 WO PCT/CN2022/119187 patent/WO2023040999A1/zh not_active Ceased
- 2022-09-16 US US18/691,672 patent/US20240382411A1/en active Pending
- 2022-09-16 EP EP22869367.7A patent/EP4403575A4/en active Pending
- 2022-09-16 AU AU2022348783A patent/AU2022348783A1/en active Pending
- 2022-09-16 JP JP2024516809A patent/JP2024535041A/ja active Pending
- 2022-09-16 CN CN202280062580.XA patent/CN118215681A/zh active Pending
-
2024
- 2024-07-10 CO CONC2024/0009127A patent/CO2024009127A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2780392T3 (es) | Anticuerpos humanos contra Fel d1 y métodos de uso de los mismos | |
| TWI911431B (zh) | 抗rsv單株抗體配製物 | |
| TWI799757B (zh) | 抗-α4β7抗體之調配物 | |
| JP2015120706A5 (https=) | ||
| WO2018236904A1 (en) | COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF | |
| KR20160079890A (ko) | 항체-약물 접합체 동결건조 제제 | |
| CN115666649B (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| US8617548B2 (en) | Methods of preventing or treating anthrax using anti-anthrax antibodies | |
| ES2699078T3 (es) | Proteínas de unión a antigeno específicas para componente amiloide sérico P | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| WO2022162587A1 (en) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection | |
| AU2021332460A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| CN110960490A (zh) | 一种抗egfr抗体偶联药物组合物及其用途 | |
| CN110305214A (zh) | 新型抗cd47抗体 | |
| US11267880B2 (en) | Anti-Sema3A antibodies and their uses for treating eye or ocular diseases | |
| WO2025091659A1 (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| JP2025539837A (ja) | Ｈｇｆｒとｅｇｆｒに特異的に結合する二重特異性抗体を含む医薬組成物 | |
| WO2022051223A1 (en) | Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19 | |
| TW202144406A (zh) | ＳＡＲＳ－ＣｏＶ－２抗體及其應用 | |
| KR20200012937A (ko) | c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도 | |
| CN114729045A (zh) | 对糖基化的ctla-4特异性的抗体及其使用方法 | |
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| JP2024535041A5 (https=) | ||
| TW202021620A (zh) | 一種cd40抗體藥物組合物及其用途 | |
| CN114786717B (zh) | 稳定的水性抗-tfpi抗体制剂 |